| European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC A Nast, P Gisondi, AD Ormerod, P Saiag, C Smith, PI Spuls, P Arenberger, ... Journal of the European Academy of Dermatology and Venereology 29 (12), 2277 …, 2015 | 547 | 2015 |
| Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients KPCM Jong EMGJ de, Seegers BAMPA, Gulinck MK Dermatology, 1996 | 399 | 1996 |
| Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study M Flendrie, WHPM Vissers, MCW Creemers, EMGJ de Jong, ... Arthritis research & therapy 7, 1-11, 2005 | 322 | 2005 |
| EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations A Nast, C Smith, PI Spuls, G Avila Valle, Z Bata‐Csörgö, H Boonen, ... Journal of the European Academy of Dermatology and Venereology 34 (11), 2461 …, 2020 | 310* | 2020 |
| β-Defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin PAM Jansen, D Rodijk-Olthuis, EJ Hollox, M Kamsteeg, GS Tjabringa, ... PloS one 4 (3), e4725, 2009 | 249 | 2009 |
| Efficacy and safety of treatments for childhood psoriasis: a systematic literature review MEA de Jager, EMGJ de Jong, PCM van de Kerkhof, MMB Seyger Journal of the American Academy of Dermatology 62 (6), 1013-1030, 2010 | 201 | 2010 |
| A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis U Mrowietz, E De Jong, K Kragballe, R Langley, A Nast, L Puig, K Reich, ... Journal of the European Academy of Dermatology and Venereology 28 (4), 438-453, 2014 | 195 | 2014 |
| Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis LLA Lecluse, RJB Driessen, PI Spuls, EMGJ de Jong, SO Stapel, ... Archives of dermatology 146 (2), 127-132, 2010 | 193 | 2010 |
| How stress gets under the skin: cortisol and stress reactivity in psoriasis AWM Evers, EWM Verhoeven, FW Kraaimaat, E De Jong, ... British Journal of Dermatology 163 (5), 986-991, 2010 | 189 | 2010 |
| Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review. EWM Verhoeven, S Klerk, FW Kraaimaat, PCM Van de Kerkhof, ... | 181 | 2008 |
| Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review EBM Kroft, NJG Berkhof, PCM van de Kerkhof, RMJP Gerritsen, ... Journal of the American Academy of Dermatology 59 (6), 1017-1030, 2008 | 180 | 2008 |
| Low-dose methotrexate in the treatment of widespread morphea MMB Seyger, FHJ van den Hoogen, T de Boo, EMGJ de Jong Journal of the American Academy of Dermatology 39 (2), 220-225, 1998 | 170 | 1998 |
| Morphea and eosinophilic fasciitis: an update JS Mertens, MMB Seyger, RM Thurlings, TRDJ Radstake, EMGJ de Jong American journal of clinical dermatology 18, 491-512, 2017 | 151 | 2017 |
| The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology‐specific health instrument AWM Evers, P Duller, PCM Van De Kerkhof, PGM Van der Valk, ... British Journal of Dermatology 158 (1), 101-108, 2008 | 150 | 2008 |
| European S3-Guideline on the systemic treatment of psoriasis vulgaris-Update Apremilast and Secukinumab-EDF in cooperation with EADV and IPC. A Nast, PI Spuls, G Kraaij, P Gisondi, C Paul, AD Ormerod, P Saiag, ... Journal of the European Academy of Dermatology & Venereology 31 (12), 2017 | 147 | 2017 |
| Drug survival studies in dermatology: principles, purposes, and pitfalls JMPA Van Den Reek, W Kievit, R Gniadecki, JJ Goeman, J Zweegers, ... Journal of Investigative Dermatology 135 (7), 1-5, 2015 | 138 | 2015 |
| Individual differences in the effect of daily stressors on psoriasis: a prospective study EWM Verhoeven, FW Kraaimaat, E De Jong, J Schalkwijk, ... British journal of dermatology 161 (2), 295-299, 2009 | 136 | 2009 |
| Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study EBM Kroft, TJ Groeneveld, MMB Seyger, EMGJ Jong American journal of clinical dermatology 10, 181-187, 2009 | 135 | 2009 |
| Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors … W Vissers, CHM Arndtz, L Muys, PEJ Van Erp, EMG De Jong, ... British Journal of Dermatology 150 (5), 852-859, 2004 | 135 | 2004 |
| Liver injury in long‐term methotrexate treatment in psoriasis is relatively infrequent MAM Berends, J Snoek, E De Jong, PCM Van De Kerkhof, ... Alimentary pharmacology & therapeutics 24 (5), 805-811, 2006 | 122 | 2006 |
Peter van de Kerkhofradboud在 radboudumc.nl 的电子邮件经过验证
